



Syntax Communications, Inc.
 305 West Country Drive
 Duluth, GA 30097-5906
 Ph: 678-584-9503 Fax: 678-584-9661

Course Evaluation Form

Proteasome Inhibition in Hematologic Malignancies: Clinical Update and Practical Applications

This continuing education course, which will be released in December 2004, is best suited for oncology pharmacists. This program was supported through an unrestricted educational grant from Millennium Pharmaceuticals and is offered to oncology pharmacists free of charge. The supplement discusses uses of bortezomib that have not been approved by the US Food and Drug Administration.

Syntax Communications, Inc.

Completion Date: _____

UPN # 299-000-04-028-H01

I certify that I have completed the above-named home study.

 Signature

**Using the subsequent scale, please answer the following evaluation questions:
 (5 = strongly agree; 4 = agree; 3 = uncertain; 2 = disagree; 1 = strongly disagree)**

- The articles were clear and to the point.
- The learning objectives were clear.
- The author provided information that will be useful in my practice.
- I found the offering to be free from commercial bias (please state any perception of commercial bias below under "other comments").

The following program objectives were achieved:

- Describe how proteasome inhibition affects tumor cell growth and survival.
- List two advantages of bortezomib over other synthetic and natural proteasome inhibitors.
- Discuss the results of clinical trials evaluating bortezomib alone or in combination with standard chemotherapy agents in the treatment of hematologic malignancies and solid tumors.
- Discuss the efficacy results of the SUMMIT and CREST trials evaluating bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma.
- List three patient or disease characteristics that predict positive outcomes (eg, longer time to disease progression or survival time) in patients with relapsed or refractory multiple myeloma receiving bortezomib therapy.
- Based on preliminary clinical trial results, describe the potential advantages and disadvantages of long-term (> 8 wk) bortezomib therapy.
- Describe the process by which the ubiquitin-proteasome pathway controls degradation of regulatory proteins.
- Describe the antitumor mechanisms of action for bortezomib.
- Discuss the pharmacokinetics and pharmacodynamics of bortezomib.
- List the most common adverse effects reported in phase II trials evaluating bortezomib as treatment of relapsed/refractory multiple myeloma.
- Recommend bortezomib dosage adjustments for patients who experience peripheral neuropathy, grade 3 or 4 nonhematologic toxicities, or grade 4 hematologic toxicities.

Drs. Laura Jung, Lisa Holle, and William Dalton, who wrote "Discovery, Development, and Clinical Applications of Bortezomib,"

- were effective presenters (authors).
- organized the material in an effective way.
- kept my attention.

Drs. Rowena Schwartz and Terri Davidson, who wrote "Pharmacology, Pharmacokinetics, and Practical Applications of Bortezomib,"

- were effective presenters (authors).
- organized the material in an effective way.
- kept my attention.

Other comments: _____

Please send my statement of credit to (PLEASE PRINT):

Name _____ Phone # _____
 Address _____ E-mail _____
